Skip to main content
Premium Trial:

Request an Annual Quote

Four European Organizations Join Life Tech's Ion AmpliSeq Exome CSP Program

NEW YORK (GenomeWeb News) – Life Technologies today announced four organizations in Europe have joined the Ion AmpliSeq Exome Certified Service Provider program.

The organizations are La Plate-Forme Séquençage et Génomique (The Sequencing and Genomics Platform) Institut Cochin, Paris; Uppsala Genome Center, Uppsala University, Sweden; CRIBI Genomics Group of the University of Padua, Italy; and Biocant, Technology Transfer Association, Portugal.

The Ion AmpliSeq Exome Certified Service Provider program is part of the Ion Certified Service Provider program. Service providers in the program using the Ion AmpliSeq Exome Kit, the Ion Proton Sequencer, and the Ion Reporter Software, are able to sequence two exomes in one run, going from DNA to results in two days, compared to six to eight weeks with other service providers, Life Tech said.

Additionally, the service requires 50 ng of DNA to perform exome sequencing, compared to as much as 3 micrograms of DNA, otherwise. The CSP program "eliminates the need to batch samples just to make the price of exome sequencing affordable," Life Tech said.

Maneesh Jain, VP of marketing, product, and program management at the company said that as demand for the program increases, it "will soon expand globally."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.